Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Much anticipated...

    Much anticipated Medanta-Manipal deal comes to halt: Report

    Farhat NasimWritten by Farhat Nasim Published On 2019-08-20T13:49:33+05:30  |  Updated On 17 Aug 2021 12:38 PM IST

    Mumbai: The much anticipated Medanta-Manipal deal worth Rs 5800 crore has come to a halt. The deal failure is reportedly the result of valuation mismatch.


    This is Manipal Group's second setback after it was earlier outbid for Fortis in 2018. Manipal Group backed by TPG made its move toward acquiring Gurugram Based Medanta Medicity by entering into exclusive negotiations with founder Dr Naresh Trehan and other investors earlier this year. However, as per recent media accounts, the group has once again failed to crack the deal due to valuation mismatch.


    Also Read: TPG-Manipal enter into Exclusive talks to Acquire Medanta- Report


    Medical Dialogues had earlier reported that Manipal's proposed entry would have seen the complete exit of private equity fund Carlyle from its five-year-old investment in Medanta. The fund had acquired a 27% stake from US-based Avenue Capital in 2013 at a valuation of $600 million (Rs 3,540 crore in 2013).


    It was reported that Founder, Naresh Trehan was likely to retain a minority stake although the details are yet to be finalised. Trehan, his family members and co-founder Sunil Sachdeva own 55% of the company. Founded in 2009, Medanta operates super speciality hospitals and clinics in Gurgaon, Lucknow, Indore, Ranchi and Sri Ganganagar.

    Also Read: Manipal bid to buyout Medanta for Rs 5800 crore: Report


    The TPG-Manipal together commenced exploratory talks with the owners of Medanta in October 2018 to buy a majority stake in the hospital chain. However, it is learnt that Manipal could not secure finances to close the deal and also the valuation mismatch led to the deal failure.


    People aware of the matter told Live Mint., "Manipal had two strong investors who were keen to fund them, but there was a valuation mismatch. The investment has to make sense for all parties."


    Had Manipal been successful in bringing in the requisite amount, it would have been parallel to the country's prestigious Apollo Hospital in terms of bed strength. However, the failure of the deal brings to halt, the dream of pan India expansion. Acquiring Medanta would have raised Manipal's bed strength from 6,000 to 9,000s. Moreover, Manipal-Medanta would have been at 1,800 beds in the NCR region.

    ApolloApollo HospitalCardiologist Trehandeal failureDelhi-NCRFortishospitals in indiaManipalManipal GroupManipal Mednata dealMedantaMedanta acquisitionMedanta HospitalNaresh TrehanNCR hospitalTPG capital
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok